|
1
|
Sun Q, Zhang J, Cao W, Wang X, Xu Q, Yan
M, Wu X and Chen W: Dysregulated miR-363 affects head and neck
cancer invasion and metastasis by targeting podoplanin. Int J
Biochem Cell Biol. 45:513–520. 2013. View Article : Google Scholar
|
|
2
|
Amente S, Lania L and Majello B: The
histone LSD1 demeth-ylase in stemness and cancer transcription
programs. Biochim Biophys Acta. 1829:981–986. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jithesh PV, Risk JM, Schache AG, Dhanda J,
Lane B, Liloglou T and Shaw RJ: The epigenetic landscape of oral
squamous cell carcinoma. Br J Cancer. 108:370–379. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Huang PH, Chen CH, Chou CC, Sargeant AM,
Kulp SK, Teng CM, Byrd JC and Chen CS: Histone deacetylase
inhibitors stimulate histone H3 lysine 4 methylation in part via
transcriptional repression of histone H3 lysine 4 demethylases. Mol
Pharmacol. 79:197–206. 2011. View Article : Google Scholar :
|
|
5
|
Yamane K, Tateishi K, Klose RJ, Fang J,
Fabrizio LA, Erdjument-Bromage H, Taylor-Papadimitriou J, Tempst P
and Zhang Y: PLU-1 is an H3K4 demethylase involved in
transcriptional repression and breast cancer cell proliferation.
Mol Cell. 25:801–812. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Barrett A, Santangelo S, Tan K, Catchpole
S, Roberts K, Spencer-Dene B, Hall D, Scibetta A, Burchell J,
Verdin E, et al: Breast cancer associated transcriptional repressor
PLU-1/JARID1B interacts directly with histone deacetylases. Int J
Cancer. 121:265–275. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lu PJ, Sundquist K, Baeckstrom D, Poulsom
R, Hanby A, Meier-Ewert S, Jones T, Mitchell M, Pitha-Rowe P,
Freemont P and Taylor-Papadimitriou J: A novel gene (PLU-1)
containing highly conserved putative DNA/chromatin binding motifs
is specifically up-regulated in breast cancer. J Biol Chem.
274:15633–15645. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Madsen B, Spencer-Dene B, Poulsom R, Hall
D, Lu PJ, Scott K, Shaw AT, Burchell JM, Freemont P and
Taylor-Papadimitriou J: Characterisation and developmental
expression of mouse Plu-1, a homologue of a human nuclear protein
(PLU-1) which is specifically up-regulated in breast cancer. Mech
Dev. 119(Suppl 1): S239–S246. 2002. View Article : Google Scholar
|
|
9
|
Catchpole S, Spencer-Dene B, Hall D,
Santangelo S, Rosewell I, Guenatri M, Beatson R, Scibetta AG,
Burchell JM and Taylor-Papadimitriou J: PLU-1/JARID1B/KDM5B is
required for embryonic survival and contributes to cell
proliferation in the mammary gland and in ER+ breast
cancer cells. Int J Oncol. 38:1267–1277. 2011.PubMed/NCBI
|
|
10
|
Coleman JA, Correa I, Cooper L, Bohnenkamp
HR, Poulsom R, Burchell JM and Taylor-Papadimitriou J: T cells
reactive with HLA-A*0201 peptides from the histone demethylase
JARID1B are found in the circulation of breast cancer patients. Int
J Cancer. 128:2114–2124. 2011. View Article : Google Scholar
|
|
11
|
Ohta K, Haraguchi N, Kano Y, Kagawa Y,
Konno M, Nishikawa S, Hamabe A, Hasegawa S, Ogawa H, Fukusumi T, et
al: Depletion of JARID1B induces cellular senescence in human
colorectal cancer. Int J Oncol. 42:1212–1218. 2013.PubMed/NCBI
|
|
12
|
Hayami S, Yoshimatsu M, Veerakumarasivam
A, Unoki M, Iwai Y, Tsunoda T, Field HI, Kelly JD, Neal DE, Yamaue
H, et al: Overexpression of the JmjC histone demethylase KDM5B in
human carcinogenesis: involvement in the proliferation of cancer
cells through the E2F/RB pathway. Mol Cancer. 9:592010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Roesch A, Fukunaga-Kalabis M, Schmidt EC,
Zabierowski SE, Brafford PA, Vultur A, Basu D, Gimotty P, Vogt T
and Herlyn M: A temporarily distinct subpopulation of slow-cycling
melanoma cells is required for continuous tumor growth. Cell.
141:583–594. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schmitz SU, Albert M, Malatesta M, Morey
L, Johansen JV, Bak M, Tommerup N, Abarrategui I and Helin K:
Jarid1b targets genes regulating development and is involved in
neural differentiation. EMBO J. 30:4586–4600. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Stalker L and Wynder C: Evaluation of
histone-modifying enzymes in stem cell populations. Methods Mol
Biol. 809:411–426. 2012. View Article : Google Scholar
|
|
16
|
Zhong LP, Pan HY, Zhou XJ, Ye DX, Zhang L,
Yang X, Chen WT and Zhang ZY: Characteristics of a cancerous cell
line, HIOEC-B(a)P-96, induced by benzo(a)pyrene from human
immortalized oral epithelial cell line. Arch Oral Biol. 53:443–452.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cao W, Feng Z, Cui Z, Zhang C, Sun Z, Mao
L and Chen W: Up-regulation of enhancer of zeste homolog 2 is
associated positively with cyclin D1 overexpression and poor
clinical outcome in head and neck squamous cell carcinoma. Cancer.
118:2858–2871. 2012. View Article : Google Scholar
|
|
18
|
Oda D and Watson E: Human oral epithelial
cell culture. I Improved conditions for reproducible culture in
serum-free medium. In Vitro Cell Dev Biol. 26:589–595. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cao W, Zhang ZY, Xu Q, Sun Q, Yan M, Zhang
J, Zhang P, Han ZG and Chen WT: Epigenetic silencing of MAL, a
putative tumor suppressor gene, can contribute to human epithelium
cell carcinoma. Mol Cancer. 9:2962010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cui Z, Cao W, Li J, Song X, Mao L and Chen
W: TRIM24 overexpression is common in locally advanced head and
neck squamous cell carcinoma and correlates with aggressive
malignant phenotypes. PLoS One. 8:e638872013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Barrett A, Madsen B, Copier J, Lu PJ,
Cooper L, Scibetta AG, Burchell J and Taylor-Papadimitriou J: PLU-1
nuclear protein, which is upregulated in breast cancer, shows
restricted expression in normal human adult tissues: a new
cancer/testis antigen? Int J Cancer. 101:581–588. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Glazer CA, Smith IM, Ochs MF, Begum S,
Westra W, Chang SS, Sun W, Bhan S, Khan Z, Ahrendt S and Califano
JA: Integrative discovery of epigenetically derepressed cancer
testis antigens in NSCLC. PLoS One. 4:e81892009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yegnasubramanian S, Haffner MC, Zhang Y,
Gurel B, Cornish TC, Wu Z, Irizarry RA, Morgan J, Hicks J, DeWeese
TL, et al: DNA hypomethylation arises later in prostate cancer
progression than CpG island hypermethylation and contributes to
metastatic tumor heterogeneity. Cancer Res. 68:8954–8967. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim SG, Kim AS, Jeong JH, Choi JY and
Kweon H: 4-Hexyl-resorcinol stimulates the differentiation of SCC-9
cells through the suppression of E2F2, E2F3 and Sp3 expression and
the promotion of Sp1 expression. Oncol Rep. 28:677–681.
2012.PubMed/NCBI
|
|
25
|
Kulkarni P, Shiraishi T, Rajagopalan K,
Kim R, Mooney SM and Getzenberg RH: Cancer/testis antigens and
urological malignancies. Nat Rev Urol. 9:386–396. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhao WF, Wang HB, Xie B, Hu LJ, Xu LH,
Kuang BH, Li MZ and Zhang X: Sp1 and Sp3 are involved in the full
transcriptional activity of centromere protein H in human
nasopharyngeal carcinoma cells. FEBS J. 279:2714–2726. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Clahsen PC, van de Velde CJ, Duval C,
Pallud C, Mandard AM, Delobelle-Deroide A, van den Broek L and van
de Vijver MJ: The utility of mitotic index, oestrogen receptor and
Ki-67 measurements in the creation of novel prognostic indices for
node-negative breast cancer. Eur J Surg Oncol. 25:356–363. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Colozza M, Azambuja E, Cardoso F, Sotiriou
C, Larsimont D and Piccart MJ: Proliferative markers as prognostic
and predictive tools in early breast cancer: where are we now? Ann
Oncol. 16:1723–1739. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Trihia H, Murray S, Price K, Gelber RD,
Golouh R, Goldhirsch A, Coates AS, Collins J, Castiglione-Gertsch M
and Gusterson BA: International Breast Cancer Study Group: Ki-67
expression in breast carcinoma: its association with grading
systems, clinical parameters, and other prognostic factors - a
surrogate marker? Cancer. 97:1321–1331. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Raman V, Martensen SA, Reisman D, Evron E,
Odenwald WF, Jaffee E, Marks J and Sukumar S: Compromised HOXA5
function can limit p53 expression in human breast tumours. Nature.
405:974–978. 2000. View
Article : Google Scholar : PubMed/NCBI
|
